ChemoCentryx, Inc., (Nasdaq: CCXI) today announced the presentation of results from its immuno-oncology program at the American Society of Clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE